Home > Insider Trading > Filing (0001209191-21-054168)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
893949	Mednax Inc.	MD	Services-Hospitals (8060)	263667538

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1208541	S Mark Ordan	1301 Concord Terrace Sunrise FL 33323	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-08-30	95,000	$17.65	303,425	No	4	M	Direct
Common Stock	Disposition	2021-08-30	95,000	$35.09	208,425	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-08-30	95,000	$17.65	95,000	$17.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
455,331		2023-10-10	No	4	M	Direct

Footnotes

Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan").
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.